Vaxart (OTCMKTS:VXRT) Stock Passes Above Two Hundred Day Moving Average – Here’s Why

Vaxart, Inc. (OTCMKTS:VXRT)’s share price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.56 and traded as high as $0.69. Vaxart shares last traded at $0.68, with a volume of 168,499 shares.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Vaxart to a “buy” rating in a research report on Friday, January 23rd.

Vaxart Price Performance

The company’s 50-day moving average is $0.69 and its 200-day moving average is $0.56. The firm has a market capitalization of $164.54 million, a price-to-earnings ratio of 4.53 and a beta of 1.18.

Vaxart (OTCMKTS:VXRT) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. The firm had revenue of $39.23 million during the quarter, compared to analyst estimates of $50.50 million. Vaxart had a net margin of 14.51% and a return on equity of 61.43%.

Institutional Investors Weigh In On Vaxart

A number of institutional investors have recently added to or reduced their stakes in VXRT. Invesco Ltd. raised its holdings in shares of Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 70,568 shares during the period. Jones Financial Companies Lllp grew its holdings in shares of Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 478,111 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Vaxart during the 1st quarter worth approximately $31,000. Creative Planning purchased a new stake in Vaxart during the second quarter worth approximately $33,000. Finally, Marshall Wace LLP purchased a new stake in shares of Vaxart in the second quarter worth about $794,000. Hedge funds and other institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.